HFS
VIR icon

Hughes Financial Services’s Vir Biotechnology VIR Stock Holding History

Hughes Financial Services’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-113
Closed -$574 – 1111
2025
Q2 		$574 Buy
+113
New +$606 ﹤0.01% 891

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hughes Financial Services's VIR Position: Q3 2025 in Review

Hughes Financial Services sold out of Vir Biotechnology (VIR) in Q3 2025, closing a stake of 113 shares — an estimated $574 sold.

Hughes Financial Services first reported a position in VIR in Q2 2025 and held it in 1 quarter. The position peaked at $574 in Q2 2025. 213 funds tracked by Wall St. Rank hold VIR as of Q3 2025.

  • Hughes Financial Services reported no remaining Vir Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Hughes Financial Services sold 113 Vir Biotechnology shares in Q3 2025, an estimated $574.
  • Hughes Financial Services first reported a position in Vir Biotechnology in Q2 2025 and held it in 1 quarter.
  • Hughes Financial Services's Vir Biotechnology position peaked at $574 in Q2 2025.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2025.

Based on Hughes Financial Services's 13F filing for Q3 2025, filed 14 Nov 2025.